✦ LIBER ✦

187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYS™) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial

✍ Scribed by Jean-Pierre Bronowicki; Denis Ouzan; Arnaud Tzanck; Tarik Asselah; Herve Desmorat; Jean-Pierre Zarski; Juliette Foucher; Marc Bourliere; Christophe Renou; Albert Tran; Pascal Melin; Christophe Hezode; Michele Chevallier; Magali Bouvier; Isabelle Lonjon-Domanec; Jean-Michel Pawlotsky

Book ID: 119530096
Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 233 KB
Volume: 38
Category: Article
ISSN: 0270-9139
DOI: 10.1016/s0270-9139(03)80230-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of peginterferon alf

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

✍ Savino Bruno; Mitchell L. Shiffman; Stuart K. Roberts; Edward J. Gane; Diethelm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB 👁 1 views

The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40 KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis

1207 High-dose peginterferon alfa-2A (40

1207 High-dose peginterferon alfa-2A (40KD) (PEGASYS) and ribavirin (COPEGUS) in patients infected with hepatitis C virus (HCV) genotype 1 who failed to respond to interferon alfa and ribavirin

✍ DIAGO, M; ROMEROGOMEZ, M; DEVALME, H; CRESPO, J; VALDECILLA, H; OLVEIRA, A; LAPA 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB

328 Comparison of 48 or 72 weeks of trea

328 Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1

✍ Thomas Berg; M. Von Wagner; H. Hinrichsen; T. Heintges; P. Buggisch; T. Goeser; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

Efficacy of peginterferon ALFA-2A (40KD)

Efficacy of peginterferon ALFA-2A (40KD) (PEGASYS) plud ribavirin for 24 weeks in genotype 1 patients with chronic hepatitis C followed by mono or combination therapy for 22 weeks: Preliminary analysis of an open, multicenter, randomized trial

✍ J.P. Bronowicki; D. Ouzan; T. Asselah; H. Desmorat; J.P. Zarski; J. Foucher; M. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 278 KB

522 Combination therapy with peginterfer

522 Combination therapy with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR)

✍ O. Weiland; M.W. Fried; S.J. Hadziyannis; G.R. Foster; D. Messinger; K. Freivoge 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 62 KB

497 An open-label, multicenter study of

497 An open-label, multicenter study of the efficacy and safety of peginterferon alfa-2A (40KD) (PEGASYS®), alone or in combination with ribavirin (COPEGUS®), in patients with HIV/HCV coinfection

✍ E. Ortega; A. Martin; C. Barros; K. Aguirrebengoa; J. Gonzalez; A. Garcia; R. Ru 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 62 KB